Professor Justin Stebbing is a Consultant Medical Oncologist based at Imperial College Healthcare NHS Trust in London.

Professor Stebbing trained in medicine at Trinity College Oxford, where he gained a triple first class degree. After completion of junior doctor posts in Oxford, he undertook a residency at The Johns Hopkins Hospital in the US, returning to London to continue his training in oncology at The Royal Marsden and St Bartholomew’s Hospitals. Professor Stebbing’s PhD research investigated the interplay between the immune system and cancer.

Professor Stebbing has published over 500 peer-reviewed papers in journals such as the Lancet, New England Journal, Blood, the Journal of Clinical Oncology, Annals of Internal Medicine, as well as writing for national newspapers and presenting new data on optimal cancer therapies at major international conferences. His focus is on new therapies in cancer, and the systemic management of patients with a variety of solid malignancies, including a number of new biomarker-based approaches, with an emphasis on circulating tumour cells. His laboratory work is concentrated on new druggable target discovery.

He is a member of the Royal College of Physicians, the American Board of Internal Medicine and the Royal College of Pathologists, and sits on the advisory Boards of five biotechnology companies. He chairs the World Vaccine Congress and is on the editorial board of a number of world leading general medical and cancer journals such as the Journal of Clinical Oncology and Oncogene and writes BMA guidelines for several cancers.

Dr Frank Saran is a Consultant Clinical Oncologist based at The Royal Marsden Hospital.

Dr Saran moved to the Marsden in 2001 and is the head of the Neuro-Oncology Unit at The Marsden. Prior to this appointment he worked as a Consultant Clinical Oncologist at Velindre Hospital, Cardiff focussing on the management of primary CNS and spinal cord tumours as well as non-conformal radiotherapy for children with malignant tumours.

His academic and clinical focus is the management of patients requiring complex radiotherapy,conformal high-precision radiotherapy aiming to maximise tumour control while minimising the risk of potential long term side effects as well as novel systemic therapy approaches in primary CNS tumours. 

Dr Saran is regularly invited to give lectures on his subjects of expertise both internationally and nationally. He is member of many societies and national working groups including ESTRO, RCR, CCLG, NCRI Paediatric CNS tumour group and SIOP-E Brain Tumour Working Group.

Dr Stephen Lloyd Morris is a Consultant Clinical Oncologist based at Guys & St Thomas’ Hospitals and Kings College Hospital in London.

After graduating from Guys and St Thomas’ medical school Dr Morris specialised in Oncology at the Royal Marsden Hospital and at Guy's and St Thomas' Hospitals.

His unique practice includes real time dynamic prostate brachytherapy. A new treatment offered to patients in the UK at Guys and St Thomas’ and privately at London Bridge Hospital. Dr Morris has extensive experience of radiotherapy for prostate cancer including the modern techniques of IMRT, IGRT and Tomotherapy.

As a world expert in cutaneous lymphoma he offers a modern Total Skin Electron Beam (TSEB) technique at Guys and St Thomas Hospitals and the St Johns Institute of Dermatology. The St Johns institute is a world leading centre of excellence for the management of cutaneous lymphoma and the national referral centre in the UK. Through his interests in technology he designed and released a free cutaneous lymphoma iPhone app that is now used world wide to assist healthcare professionals managing cutaneous lymphoma.

Dr Morris is a Member of the Royal College of Radiologists, the British Institute of Radiology, the British Medical Association and is an active member of the EORTC cutaneous lymphoma task force and principal investigator for new drug and radiotherapy trials for cutaneous lymphoma and prostate cancer.

Professor Robert Leonard is a Professor of Medical Oncology based at Imperial College, London.

Prof Leonard originally trained and qualified at Charing Cross Hospital, where he was awarded the Clinical Gold Medal and six of the final year prizes. He Undertook Post-graduate research Fellowships at Oxford’s Radcliffe Infirmary and Harvard Medical School and later went to to become Professor of Medical Oncology at Swansea Medical School and Director of the South West Wales Cancer Institute. His current roles include Professor of Cancer Studies and Chief of Service for Medical Oncology at Imperial College, London.

Robert is a medical oncologist with a major interest in the management of breast cancer. He is a co-founder and Medical Director for  Maggies’ Cancer Caring Centres UK, and has chaired the professional advisory board. Since 2009 he has been Chair of the Scientific Board for  Breast Cancer Care UK. He set up and Chairs the  International Anglo Celtic Collaborative Oncology Trials Group. He is author/co-author of more than 350 peer reviewed original papers and reviews. He has been a senior advisor to Cancer Research UK and is lead investigator several previous and current UK clinical Trials. He also regularly acts as expert oncology witness for legal cases.

Professor Leonard is multi-lingual speaking English, French and Spanish.

Dr Paul Ross is a Consultant Medical Oncologist based at Guy’s & St Thomas’ NHS Foundation Trust, London, where he is Clinical Lead for Chemotherapy and he also consults from King’s College Hospital.  He was appointed Consultant in 2004.

Dr Ross graduated from Guy’s hospital, London after training at the Royal Marsden Hospital and complered a PhD at the institute for cancer research. 

He treats patients with colorectal cancer, oesophago-gastric cancer, pancreatic cancer, malignancies of the bile duct and gall bladder (cholangiocarcinoma) and primary liver cancer (hepatocellular cancer). In addition Dr Ross treats patients with neuroendocrine (carcinoid) tumours. He is focused on treating patients with cancer with chemotherapy and biological therapies. He has an interest in the use of locoregional therapies for liver tumours including SIRT.

Dr Ross is a member of the London Cancer New Drugs, which advises on the introduction of new drugs throughout the London area and their prioritisation.. He is Treasurer of the Association of Cancer Physicians of the United Kingdom. He is also a member of the advanced disease subgroup of the NCRI Colorectal Clinical Studies Group. 

He has been awarded the McElwain Prize, Association of Cancer Physicians in 2002 and previously in 2001 he was awarded the ASCO Merit Award, American Society of Clinical Oncology.

Professor Hani Gabra is a Professor of Medical Oncology based at Imperial College London.

Professor Gabra studied Medicine at the University of Glasgow. He graduated with a BSc (Hons) in Molecular Biology and MB ChB in 1987. He went on to complete his specialist training in Cancer Medicine in Edinburgh and then on to the Imperial College London.

His clinical work is conducted at the Hammersmith Hospital and the Queen Charlotte Hospital for Women. He runs a large evidence based/research led clinical practice providing medical oncology services for women with gynaecological cancer, embedded within a comprehensive large multidisciplinary team. He also provides a clinical trials service encompassing all phases of clinical research, and has interests in upper gastrointestinal cancer and adenocarcinoma of unknown primary.

Professor Gabra is also Chief of Service of the West London Gynaecological Cancer Centre based at Queen Charlotte's/Hammersmith Hospital and is also head of the Section of Molecular Therapeutics in the Department of Oncology at Imperial College and Director of the Ovarian Cancer Action (HHMT) Research Unit, a core funded research unit based at Imperial College London. In addition he also has an additional role as Strategic Theme Leader for Cancer Research at Imperial College.